Hutchmed (China)
HCM
Constellation Brands
STZ
Collegium Pharmaceutical
COLL
Enerpac Tool
EPAC
Ermenegildo Zegna NV
ZGN
US Stock MarketDetailed Quotes
CERO CERo Therapeutics
- 1.790
- -0.090-4.79%
Close Feb 19 16:00 ET
- 1.840
- +0.050+2.79%
Post 19:04 ET
5.42MMarket Cap0.00P/E (TTM)
1.872High1.720Low143.96KVolume1.860Open1.880Pre Close260.98KTurnover5.87%Turnover Ratio0.00P/E (Static)3.03MShares1095.00052wk High-0.74P/B4.39MFloat Cap1.70052wk Low--Dividend TTM2.45MShs Float1280.000Historical High--Div YieldTTM8.08%Amplitude1.700Historical Low1.812Avg Price1Lot Size
About CERo Therapeutics Company
CERo Therapeutics Holdings, Inc. is an immunotherapy company, which engages in development of engineered T cell therapeutics for the treatment of cancer. Its platform is designed to redirect patient-derived T cells to eliminate tumors, creating Chimeric Engulfment Receptor T (CER-T) cells used for spanning hematological malignancies and solid tumors. The company was founded on June 8, 2021 and is headquartered in Oakland, CA.
Company Profile
SymbolCERO
Company NameCERo Therapeutics
Listing DateNov 30, 2021
Founded2021
CEOMr. Chris Ehrlich
MarketNASDAQ
Employees9
Fiscal Year Ends12-31
Address201 Haskins Way,Suite 230
CityOakland
ProvinceCalifornia
CountryUnited States of America
Zip Code94080
Phone1-215-731-9450
Websitehttp://www.cero.bio
Company Executives
- Name
- Position
- Salary
- Chris Ehrlich
- Interim Chairman of the Board and Chief Executive Officer
- --
- Daniel Corey, M.D.
- Chief Technical Officer and Director
- 376.04K
- Andrew Albert Kucharchuk
- Chief Financial Officer
- --
- Dr. Kristen Pierce, PhD
- Chief Development Officer
- --
- Kathleen D. Laporte
- Director
- --
- Brian G. Atwood
- Director
- --
- Michael Byrnes
- Director
- --
- Shami J. Patel
- Director
- --
- Dr. Lindsey Rolfe, M.D.
- Independent Director
- --